期刊文献+

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease 被引量:20

原文传递
导出
摘要 The mammalian target of rapamycin(mTOR)is a protein kinase that controls cellular metabolism,catabolism,immune responses,autophagy,survival,proliferation,and migration,to maintain cellular homeostasis.The mTOR signaling cascade consists of two distinct multi-subunit complexes named mTOR complex 1/2(mTORC1/2).mTOR catalyzes the phosphorylation of several critical proteins like AKT,protein kinase C,insulin growth factor receptor(IGF-1R),4E binding protein 1(4E-BP1),ribosomal protein S6 kinase(S6K),transcription factor EB(TFEB),sterol-responsive element-binding proteins(SREBPs),Lipin-1,and Unc-51-like autophagy-activating kinases.mTOR signaling plays a central role in regulating translation,lipid synthesis,nucleotide synthesis,biogenesis of lysosomes,nutrient sensing,and growth factor signaling.The emerging pieces of evidence have revealed that the constitutive activation of the mTOR pathway due to mutations/amplification/deletion in either mTOR and its complexes(mTORC1 and mTORC2)or upstream targets is responsible for aging,neurological diseases,and human malignancies.Here,we provide the detailed structure of mTOR,its complexes,and the comprehensive role of upstream regulators,as well as downstream effectors of mTOR signaling cascades in the metabolism,biogenesis of biomolecules,immune responses,and autophagy.Additionally,we summarize the potential of long noncoding RNAs(lncRNAs)as an important modulator of mTOR signaling.Importantly,we have highlighted the potential of mTOR signaling in aging,neurological disorders,human cancers,cancer stem cells,and drug resistance.Here,we discuss the developments for the therapeutic targeting of mTOR signaling with improved anticancer efficacy for the benefit of cancer patients in clinics.
出处 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2023年第11期5159-5183,共25页 信号转导与靶向治疗(英文)
基金 We would like to acknowledge the support by the Department of Biotechnology(DBT),Government of India under its Ramalingaswami Fellowship(BT/RLF/Re-entry/24/2014) Indian Council of Medical Research(ICMR)Adhoc grant(No.5/13/6/2022/NCD-Ⅲ,2021-12187)awarded to Prof.(Dr.)Manoj Garg Aishwarya Singh is highly thankful to the ICMR for providing a junior research fellowship under the guidance of Prof.Manoj Garg The authors wish to acknowledge the DBT/Wellcome Trust India Alliance Fellowship[IA/E/17/1/503663]awarded to Dr.Shinjinee Sengupta for financial support.
作者简介 Correspondence:Shinjinee Sengupta,shin143@gmail.com;Correspondence:Deepak Kumar,guptadeepako02@gmail.com;Correspondence:Manoj Garg,nuscsimg@gmail.com;contributed equally:Vivek Panwar;contributed equally:Aishwarya Singh。
  • 相关文献

参考文献12

二级参考文献78

  • 1Fei Ren,Wei-Qi Sheng,Xiang Du.CD133:A cancer stem cells marker, is used in colorectal cancers[J].World Journal of Gastroenterology,2013,19(17):2603-2611. 被引量:19
  • 2Clement V Sanchez P de Tribolet N Radovanovic I Ruiz i Altaba A.HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity[J].中国神经肿瘤杂志,2007,5(2):122-122. 被引量:97
  • 3Laplante M, Sabatini DM. Cell 2012; 149:274-293.
  • 4Sarbassov dD, Ali SM, Sengupta S, et al. Mol Cell 2006; 22:159-168.
  • 5Yin Y, Hua H, Li M, et al. Cell Res 2016; 1:46-65.
  • 6Kim S J, DeStefano MA, Oh W J, et al. Mol Cell 2012; 48:875-887.
  • 7Yu Y, Yoon SO, Poulogiannis G, et al. Sci- ence 2011 ; 332:1322-1326.
  • 8Hsu PP, Kang SA, Rameseder J, et al. Sci- ence 2011 ; 332:1317-1322.
  • 9Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009; 152: 239-62.
  • 10Milosevic 2, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, et al. Targeting RAS-MAPK-ERK and PI3K-AKT-mT0R signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res 2014; 164: 411-23.

共引文献231

同被引文献137

引证文献20

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部